SG Americas Securities LLC bought a new stake in shares of RXi Pharmaceuticals Corp (NASDAQ:RXII) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 118,387 shares of the biotechnology company’s stock, valued at approximately $228,000.
RXII has been the subject of several recent research reports. HC Wainwright set a $3.00 target price on shares of RXi Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 15th. ValuEngine upgraded shares of RXi Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd.
RXII opened at $1.19 on Wednesday. The company has a market capitalization of $5.25 million, a price-to-earnings ratio of -0.28 and a beta of 1.29. RXi Pharmaceuticals Corp has a 1-year low of $1.12 and a 1-year high of $7.70.
RXi Pharmaceuticals (NASDAQ:RXII) last posted its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.16. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.02 million. sell-side analysts anticipate that RXi Pharmaceuticals Corp will post -2.14 EPS for the current year.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.
Featured Story: Dividend Aristocrat Index
Want to see what other hedge funds are holding RXII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RXi Pharmaceuticals Corp (NASDAQ:RXII).
Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.